Posted: June 2017 FDA Warns of Fraudulent Cancer Drugs On April 25, 2017, the US Food and Drug Administration (FDA) issued warning letters to 14 companies regarding more than 65 […] Read more
Posted: April 2017 By Erik T. MacLaren, PhD On January 11, the National Cancer Institute (NCI) launched a virtual agent formulary (NCI Formulary): a new public-private partnership designed to speed […] Read more
Interview with Dara Corrigan, JD: United States to Implement Mutual Recognition Agreement with European Union
Posted: April 2017 *Erik T. MacLaren, PhD, is acknowledged for his editorial support of this article. On March 2, 2017, the European Union (EU) and the US announced the Mutual […] Read more
Posted: February 2017 BY Erik J. Maclaren, PhD Breakthrough Therapy Designation and Mechanisms of Expedited Review The U.S. Food and Drug Administration (FDA) is responsible for reviewing the evidence of […] Read more
Posted: February 2017 By Erik J. Maclaren, PhD 2017 Mesothelioma Clinical Trials Planning Meeting Malignant mesothelioma is one of the most difficult cancers to control using existing therapies. Due to […] Read more
By Stephanie R. Land, PhD Tobacco cessation assistance, imperative for tobacco users who seek medical care,1 takes on even greater urgency for individuals who are undergoing cancer screening or treatment. […] Read more
BY ERIK J. MACLAREN, PHD In May 2016, the U.S. Food and Drug Administration (FDA) finalized the deeming rule that extended the agency’s regulatory authority to include all tobacco products, […] Read more
FDA Corner – Interview with Reena Philip, PHD, and Eunice Lee, PHD
By Erik J. MacLaren, PhD Liquid Biopsy Testing On June 1, 2016, the U.S. Food and Drug Administration (FDA) approved the use of the cobas EGFR Mutation Test v2 to […] Read more
By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory BoardDuring his State of the Union address in January 2016, President Barack Obama announced a new […] Read more
By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago is still gaining momentum. Seminal […] Read more